Cell Reprogramming Market to Grow with a CAGR of 8.14% through 2028
Rising prevalence of chronic diseases and personalized
medicine and drug discovery are factors driving the Global Cell Reprogramming Market in the forecast period 2024-2028.
According to
TechSci Research report, “Cell Reprogramming Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the
Global Cell Reprogramming Market stood at USD 325.45 million in 2022 and is
anticipated to grow with a CAGR of 8.14% in the forecast period, 2024-2028. The
field of regenerative medicine has witnessed remarkable advancements in recent
years, thanks to groundbreaking innovations in cell reprogramming. Cell
reprogramming, the process of converting one cell type into another with
distinct functions, has opened up new avenues for disease modeling, drug
discovery, and tissue regeneration. As a result, the global cell reprogramming
market has experienced significant growth, driven by a combination of factors
that are shaping the future of healthcare and biotechnology.
Regenerative
medicine holds great promise for addressing a wide range of medical conditions,
from degenerative diseases to organ transplantation. Cell reprogramming is a
key enabler of regenerative medicine, as it can generate patient-specific cells
for transplantation and tissue engineering. The potential to replace damaged or
diseased tissues with regenerated ones is a compelling driver for both research
and commercial applications.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Cell Reprogramming Market.”
One of the
primary drivers of the cell reprogramming market is the increasing prevalence
of chronic diseases such as diabetes, Alzheimer's disease, and heart disease.
These conditions impose a significant burden on healthcare systems worldwide.
Cell reprogramming offers the potential to develop patient-specific cell models
for disease research, enabling the discovery of novel therapies and personalized
treatment options.
Recent
breakthroughs in gene editing technologies, most notably CRISPR-Cas9, have
revolutionized the field of cell reprogramming. These tools allow researchers
to precisely manipulate the genome of cells, facilitating the creation of
induced pluripotent stem cells (iPSCs) and other reprogrammed cell types. This
increased precision and efficiency have accelerated research efforts and
expanded the possibilities for therapeutic applications.
The Global Cell
Reprogramming Market is segmented into Technology, Application, End user and
company.
Based on application,
the research
segment has emerged as the predominant market leader. The growth of the cell reprogramming market is
reflected in the increasing investment and funding pouring into research
initiatives. Both public and private sectors recognize the transformative
potential of cell reprogramming technology and are channeling resources
accordingly. Academic institutions, biotechnology companies, and pharmaceutical
giants are actively engaged in collaborative efforts to drive innovation.
Based on region,
North America segment is expected to grow during the forecast period. North America has established a favorable regulatory
framework for regenerative medicine and cell reprogramming therapies. The U.S.
Food and Drug Administration (FDA) has been proactive in adapting regulations
to support the development of advanced therapies, providing a conducive
environment for companies in this sector. North
American companies are at the forefront of developing cutting-edge
technologies, including genome editing tools like CRISPR-Cas9, which complement
cell reprogramming efforts. These advancements enhance the precision and
efficiency of cell reprogramming techniques.
The Asia Pacific
region is experiencing rapid market growth. The region's healthcare market is
characterized by a high demand for advanced therapies and regenerative medicine
solutions. North American companies are well-positioned to capitalize on this
demand and bring cell reprogramming products and services to market.
Major companies
operating in Global Cell Reprogramming Market are:
- Allele
Biotechnology co. ltd.
- ALSTEM, INC
- Applied
Biological Materials Inc.
- Axol
Bioscience Ltd.
- Fujifilm
Cellular Dynamics inc.
- Lonza Group
AG
- Mogrify
inc.
- REPROCELL
Inc.
- Stemnovate
Limited
- Thermo
Fisher Scientific Inc
Download Free Sample Report
Customers can
also request 10% free customization in this report.
“The global cell
reprogramming market is poised for significant expansion in the coming years,
driven by a convergence of factors. The rising prevalence of chronic diseases,
advances in gene editing technologies, increased investment in biotechnology,
and the promise of personalized medicine and regenerative therapies are all
contributing to the growth of this dynamic industry. As the field continues to
evolve, we can expect even more innovative applications and groundbreaking
discoveries in the realm of cell reprogramming, ultimately transforming the
landscape of healthcare and biotechnology.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Cell Reprogramming Market By Technology (Sendai Virus-based, mRNA Reprogramming, Others),
By Application (Research, Therapeutic), By End User (Research & Academic Institutes,
Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, Others)),
By Region, By Competition Forecast
& Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Cell Reprogramming Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cell Reprogramming Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan,
NY,
New York
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com